Selected price target: $200 per share — roughly the consensus Wall Street analyst price target and a round-number milestone just below the stock's 52-week high. Current position: Shares trade near $126, well below the $212.12 52-week high reached after the BRINSUPRI approval, meaning a move to $200 implies roughly 58% upside.

Target in focus: $400 per share, roughly 50% above ALNY's recent trading range near $265 and closely aligned with the analyst consensus of about $394–$412. Strongest bullish factor: Rapid uptake of AMVUTTRA in transthyretin amyloidosis cardiomyopathy (ATTR-CM), with the TTR franchise exceeding $1 billion in quarterly revenue.

Selected price target: $9, matching the Wall Street consensus analyst price target, versus a recent share price near $3. Strongest bullish factor: Positive clinical data for lead drug candidate tegoprubart in kidney and islet cell transplantation, with a Phase 3 kidney transplant program now in planning.

The central question is whether Immunic can climb from roughly $13 to a $20 price target, a psychological round-number milestone that sits just below the low end of most Wall Street targets. The strongest bullish catalyst is the Phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (MS), with top-line data expected by the end of 2026.

Denali Therapeutics shares closed near $22.28 , leaving a $30 price target roughly 35% above the latest close. Wall Street remains broadly constructive, with an average analyst price target near $35 and individual targets ranging from about $27 to $42.

MLTX shares declined roughly 14.5% over the trailing 30 days, from $17.55 on August 5, 2026, to $15.01 on September 4, 2026. The pullback followed positive Phase 3 IZAR-1 topline data for sonelokimab in psoriatic arthritis, as investors sold the news amid the absence of placebo-comparison figures.

Price target in focus: $30 per share, roughly double the stock's recent trading level near $15. Strongest bullish factor: An expected Biologics License Application (BLA) for lead drug candidate sonelokimab, planned for September 2026.

Biomea Fusion shares climbed approximately 61% over the last 30 days, rising from about $1.26 to about $2.03. The advance accelerated in late August after the company completed enrollment in its COVALENT-211 Phase II diabetes trial, a move that triggered an unusually large spike in trading volume.

The central question is whether Impact BioMedical, Inc. (IBO) can reclaim the $1.00 level, a widely watched psychological milestone. With the stock recently trading near $0.65, reaching $1.00 would require a gain of roughly 50% from current levels.

NTHI is trading up +7.1% to $5.13 during regular market hours, versus a $4.79 prior-session close. The gain extends momentum from its positive Phase 2a NEO100 topline results (48.9% six-month progression-free survival vs. a 20% benchmark; median overall survival ~26.1 months) in recurrent IDH1-mutant high-grade glioma.

Late-stage pipeline readouts — including fianlimab in first-line melanoma and complement-inhibitor data in geographic atrophy and PNH (paroxysmal nocturnal hemoglobinuria, a rare blood disorder) — are expected through 2026 and could broaden Regeneron's commercial base. Dupixent and Eylea HD remain the core growth engines, with label expansions and a prospective Eylea HD prefilled syringe approval seen as near-term demand drivers.

INO shares climbed roughly 105% over the past 30 days, rising from about $0.66 to around $1.36. The rebound followed a sharp late-July selloff tied to a $20 million equity offering that diluted existing shareholders.

RARE shares are down -46.85%, sliding from a $26.53 prior close to roughly $14.10 intraday. The drop began after-hours Wednesday after Ultragenyx disclosed its Phase 3 Aspire study of apazunersen (GTX-102) for Angelman syndrome failed to meet its primary and key secondary endpoints.

Halozyme Therapeutics (HALO) rose roughly 31.8% over the last 30 days, climbing from about $83.23 to $109.66. The move was driven primarily by record second-quarter 2026 results, raised full-year guidance, and accelerated share repurchases.

The selected price target is $10 per share , roughly a 110% gain from recent trading near $4.73 and below the stock's 52-week high of $12.99. Wall Street is notably bullish: the consensus analyst price target is $16 , with individual targets ranging from $13 to $20.

NTHI is up +5.92% during regular-session trading, climbing to roughly $5.01 from a $4.73 prior close. The gain follows a -4.25% pullback on Sept 1, reflecting sustained high volatility in this micro-cap clinical-stage biotech.

Purple Biotech (PPBT) has climbed roughly 73% over the trailing 30 days, from about $1.47 in early August to around $2.55. A U.S. patent Notice of Allowance covering tri-specific antibody designs from its CAPTN-3 platform was the primary catalyst, triggering unusually heavy trading volume.

The widely cited 12-month analyst price target for PPBT is $17 , implying a roughly tenfold move from recent prices in the $1.50–$2.30 range. The bullish case rests on the CAPTN-3 tri-specific antibody platform and lead candidate IM1240, which is advancing toward a first-in-human Phase 1 trial.

ALMS plunged roughly -53% (about $10.22 vs. prior close $21.81) in premarket trading before reopening lower at the open. Primary catalyst: the Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus missed its primary and secondary endpoints in the overall population.

Insmed (INSM) shares rose roughly 23.5% over the past 30 days, from about $98.60 to $121.82, driven primarily by a strong second-quarter 2026 earnings report and raised guidance. The stock surged approximately 34% in a single session on August 6, 2026, after the company reported sharply narrower losses and nearly quadrupled product revenue.